Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 5/20 | 0.61 |
| ▸ | ALB | P02768 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | UTRN | P46939 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12704771 | 0.90 | HDAC6 (0.61) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL460247 | 0.85 | TTR (0.69) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL12704769 | 0.81 | TTR (0.60) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL12704759 | 0.81 | TTR (0.66) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL12704761 | 0.81 | TTR (0.66) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL1675530 | 0.79 | MAOA (0.56) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL12704780 | 0.79 | TTR (0.60) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL12704758 | 0.79 | TTR (0.60) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL20897632 | 0.78 | TTR (0.78) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL1675377 | 0.77 | TTR (0.68) | TTRALBMAOACNR1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | claimed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | claimed |
| US-8338459-B2 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | FOLDRX PHARMACEUTICALS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338459-B2 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | FOLDRX PHARMACEUTICALS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2314584-A1 | 2-(heteroaryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | Foldrx Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20110092545-A1 | Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding | FoldRx Pharmaceuticals, Inc., a Massachusetts corporation | 2011-04-21 | — | — | US | disclosed |
| US-20110092545-A1 | Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding | FoldRx Pharmaceuticals, Inc., a Massachusetts corporation | 2011-04-21 | — | — | US | disclosed |
| US-7868033-B2 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | FOLDRX PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868033-B2 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | FOLDRX PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092545-A1 | Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding | TTR, ALB, TTPA | TTR 1/4885ALB 2/4885MAOA 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.